Charles River Laboratories International stock
CRLNYSECharles River Laboratories International, Inc., HealthcareISIN US1598641074
55Score 55 out of 100, Neutral
Price and trend
82 / 100
Price history
+99% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 50% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 9.4% below its 52-week high. Largest decline in 20 years: 78% (September 2021 to April 2025).
Chart figures for advanced users
- SMA 50$310.17
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$227.08
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$149.93
- The lowest closing price of the last twelve months.
- Resistance$376.10
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Charles River Laboratories International, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $16.33B, is number 17 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.02B (down 0.9% year on year) and a loss of $144.34M.
- For fiscal 2026, analysts expect on average revenue of $3.94B (down 2%) and adjusted earnings per share of $11.45 (up 11.4%).
Show more
- MEQIRI Score 55 out of 100 (Neutral): rank 332 of 714 in Healthcare, median 53.
- The P/E is 412 (Medical (Diagnostics & Research) median 33.7, own median of recent years 27.5).
- Our model puts fair value at $131.67, with the price 160% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.Fundamentals 81
Weaknesses
- Interest barely coveredOperating profit covers interest only 0.1 times.Stability 45
- Richly valuedP/E 412, Medical (Diagnostics & Research) median 33.7, own median 27.5.Valuation 12
- Above fair valuePrice 160% above the fair value of $131.67.Valuation 12
Its standout strengths are momentum and technical analysis, while profitability and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- price up very strongly over the past year
What lowers it
- solid fundamentals
- stable momentum
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $94.05 and expensive above $219.45 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $235.43 (cash-flow model) and $27.91 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.7%. At 10.7% the fair value would be $113.91, at 8.7% it would be $156.74.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (33.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 26 Sep 2026, revenue fell 1.2% on the twelve months before. Revenue has grown solidly since 2006, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 31%, operating 13%, net −4%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 17 Feb 2027in 97 days
- Last reported
- 4 Nov 2026EPS reported $3.09 (expected $2.97)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $11.45+0.7%
- Revenue
- $3.94B+0.5%
- Earnings per share
- $12.89+0.6%
- Revenue
- $4.04B+0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +13.4%2026 financial guidance raised, DSA outlook raised to low single-digit organic revenue growth; second quarter exceeded the company's prior outlook.
“As a result of these collective trends, we have raised our DSA outlook to low single-digit organic revenue growth in 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $2,974 in total. 6 insiders sold, $52.07M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Foster James CSale
22 Oct 2026, Board
- Shares
- 24,042
- Price
- $350.00
- Value
- $8.41M
- Parisotto Shannon MSale
21 Oct 2026, CEVP, Disc & Safety Assessment
- Shares
- 2,156
- Price
- $344.41
- Value
- $742,548
- Parisotto Shannon MSale
5 Oct 2026, CEVP, Disc & Safety Assessment
- Shares
- 981
- Price
- $308.44
- Value
- $302,580
Show 11 more
- Coleman GlennPurchase
30 Sept 2026, EVP & Chief Financial Officer
- Shares
- 10
- Price
- $297.43
- Value
- $2,974
- Foster James CSale
25 Aug 2026, Board
- Shares
- 33,561
- Price
- $300.00
- Value
- $10.07M
- Parisotto Shannon MSale
19 Aug 2026, CEVP, Disc & Safety Assessment
- Shares
- 2,039
- Price
- $294.12
- Value
- $599,711
- Andrews Nancy CSale
18 Aug 2026, Board
- Shares
- 573
- Price
- $285.24
- Value
- $163,443
- Girshick BirgitSale
11 Aug 2026, Chief Executive Officer
- Shares
- 6,500
- Price
- $279.90
- Value
- $1.82M
- Parisotto Shannon MSale
11 Aug 2026, CEVP, Disc & Safety Assessment
- Shares
- 3,714
- Price
- $279.66
- Value
- $1.04M
- Foster James CSale
10 Aug 2026, Board
- Shares
- 28,733
- Price
- $275.00
- Value
- $7.9M
- Knell Michael GunnarSale
6 Aug 2026, SVP, Finance and CAO
- Shares
- 6,645
- Price
- $260.38
- Value
- $1.73M
- Creamer Victoria LSale
6 Aug 2026, EVP & Chief People Officer
- Shares
- 4,179
- Price
- $259.16
- Value
- $1.08M
- Parisotto Shannon MSale
5 Aug 2026, CEVP, Disc & Safety Assessment
- Shares
- 5,046
- Price
- $263.00
- Value
- $1.33M
- Foster James CSale
29 Jun 2026, Board
- Shares
- 75,000
- Price
- $225.00
- Value
- $16.88M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Charles River Laboratories International
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 55
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- Guardant HealthGH $20.94B45
- Medpace HoldingsMEDP $18.59B83
- RevvityRVTY $17.66B56
- Eurofins ScientificERF.PA $17B61
- ICON PublicICLR $14.96B62
- bioMérieuxBIM.PA $12.07B70
- WuXi XDC Cayman2268.HK $11.62B73
- QiagenQGEN $10.39B76
ETFs that hold Charles River Laboratories International
Held by 34 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.70% | 0.49% | €318.39M |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.47% | 0.40% | €1.49B |
| Amundi Global Gender Equality UCITS ETF AccVOOM | 0.71% | 0.20% | €55.72M |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.29% | 0.43% | €2.48B |
| Xtrackers S&P 500 Equal Weight UCITS ETF 1CXDEW | 0.25% | 0.15% | €14.88B |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.24% | 0.39% | €188.08M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.23% | 0.15% | €3.27B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.23% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 27 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.